Abstract 30P
Background
Colorectal cancer (CRC) stands as a formidable contributor to cancer-related mortality globally, motivating ongoing efforts to enhance diagnostic and therapeutic strategies. Among emerging candidates, Suppressor of Cytokine Signalling 6 (SOCS6) has garnered attention for its potential implications in tumorigenesis, including CRC. Previously, dot blot technique revealed that SOCS6 binds to multiple candidates, including the erythropoietin receptor (EPOR), which is known to have role in cancer development. Therefore, SOCS6 could regulate the expression of EPOR to facilitate CRC progression. However, the differential expression patterns of SOCS6 and its correlation with EPOR in CRC is not well elucidated. This study aims to correlate expression levels of SOCS6 with the clinical outcomes using immunohistochemistry and to investigate the functional role of SOCS6 along with its correlation with EPOR in CRC.
Methods
Immunohistochemical staining was performed on a total of 80 formalin-fixed, paraffin-embedded CRC specimens, including 70 cancerous and 10 normal tissues, to unveil SOCS6 expression patterns. Moreover, to investigate the role, SOCS6 was silenced using siRNA and functional assays (cell proliferation, and wound healing) were performed in CRC cell lines (HT-29 and COLO-320DM). Also, qRT-PCR, and western blot were conducted to determine the correlation between SOCS6 and EPOR.
Results
Immunohistochemistry revealed a reduction in SOCS6 expression in CRC specimens compared to the normal tissue, yet not significantly associated with tumour stage or grade. Molecular investigations elucidated significant increase in cell proliferation in SOCS6 silenced HT-29 and COLO-320DM cells, demonstrating its tumor suppressive function. In terms of wound healing assay, the gap closure was significantly higher only in SOCS6 silenced COLO-320DM cells. In addition, silencing SOCS6 resulted in the upregulation of EPOR in COLO-320DM cells, however EPOR levels were reduced in HT-29 cells.
Conclusions
Our current findings suggest the tumour suppressive role of SOCS6 in CRC, with the potential to serve as a diagnostic and therapeutic marker.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Sultan Qaboos University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4P - Predicting triple-negative breast cancer molecular subtype from hematoxylin and eosin using deep neural networks
Presenter: Nicola Occelli
Session: Cocktail & Poster Display session
Resources:
Abstract
5P - Onconaut: A precision medicine platform for oncology therapies
Presenter: Altuna Akalin
Session: Cocktail & Poster Display session
Resources:
Abstract
6P - Diagnostic accuracy of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry slides: A systematic review and meta-analysis
Presenter: Daniel Arruda Navarro Albuquerque
Session: Cocktail & Poster Display session
Resources:
Abstract
8P - Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers
Presenter: Sofia Merajver
Session: Cocktail & Poster Display session
Resources:
Abstract
9P - Circulating tumor cells and circulating tumor DNA detection in colorectal cancer stage III patients receiving three or six months of adjuvant treatment
Presenter: Asimina Koulouridi
Session: Cocktail & Poster Display session
Resources:
Abstract
10P - Novel theranostic agents in non-metastatic Egyptian breast cancer patients: miR-96, miR-1275, miR-4317 and miR-744
Presenter: Ahmed Mokhtar
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - A prospective study to evaluate the prognostic implications and molecular mechanism of SLC40A1 gene in primary acute myeloid leukemia
Presenter: Harsh Goel
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Prognostic value of PD-L1 expression and neutrophil-to-lymphocyte ratio to neoadjuvant chemo-immunotherapy in muscle-invasive urothelial carcinoma patients from the AURA trial
Presenter: Jeremy Blanc
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - Methylation of BRCA1 and RAD51C promoters determined by droplet digital PCR predicts homologous repair deficiency in patients with high-grade serous ovarian cancer: Results of the BOVARY-pilot study in paired FFPE and plasma samples and the ICL ovarian cohort
Presenter: Cassandra Michel
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - SLFN11 detection in patients with small cell lung cancer treated with lurbinectedin: A retrospective translational analysis
Presenter: Daniela Scattolin
Session: Cocktail & Poster Display session
Resources:
Abstract